Heartware International has seen analysts pump their estimates higher, giving love to this medical device company love and not heartache.

FORBES: HeartWare Beating Away, Pulse Still Strong

HeartWare is a global medical device company dedicated to delivering safe, high-performing and transformative therapies that enable patients with heart failure to get back to life.

FORBES: HeartWare Beating Away, Pulse Still Strong

The FDA said today that it had granted approval to the HeartWare Ventricular Assist System for use in heart failure patients waiting for a transplant.

FORBES: HeartWare LVAD Approved By FDA For Transplant Patients

HeartWare said that the FDA was requiring the company to perform a post-approval study in the form of a registry consisting of 600 HeartWare patients and an additional 600 control patients.

FORBES: HeartWare LVAD Approved By FDA For Transplant Patients

Click here for the HeartWare press release.

FORBES: HeartWare LVAD Approved By FDA For Transplant Patients

HeartWare rose on an analysis presented at the annual meeting of the American Heart Association that showed its device for helping the hearts of transplant patients pump may outperform that of rival Thoratec, which was one of the biggest decliners.

FORBES: November's Best- and Worst-Performing Biotech Stocks